Qiagen and Incyte have announced a master collaboration agreement to create a diagnostic panel to aid in the treatment of individuals with a group of rare blood cancers known as myeloproliferative neoplasms (MPNs).
This partnership focuses on supporting Incyte’s investigational therapies, including the monoclonal antibody INCA033989, which targets mutant calreticulin (mutCALR) in conditions such as myelofibrosis (MF) and essential thrombocythemia (ET).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the agreement, Qiagen will create a multimodal panel leveraging next-generation sequencing (NGS) to detect clinically relevant gene alterations in haematological malignancies.
The validation of the panel will be done by the Illumina NextSeq 550Dx platform as part of Qiagen’s collaboration with the latter to provide NGS diagnostic platforms for global laboratory testing.
Regulatory submissions and market access activities will be supported by Qiagen across the European Union, the US, and the Asia-Pacific regions.
According to Qiagen, MPNs account for approximately 40% of haematological malignancies and are marked by the overproduction of various mature blood cells.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIncyte research and development head and president Pablo Cagnoni said: “Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with Qiagen, which will facilitate CALR testing for patients with MPNs on a global basis.
“The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF.”
Incyte’s INCA033989 for mutCALR ET or MF aims to eliminate malignant cells while sparing healthy ones.
CALR is said to play a crucial role in managing calcium levels within cells and ensuring the production of proteins.
Last month, Qiagen entered a commercial collaboration and joint marketing agreement with ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for applications in oncology research.
